Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions

Figures & data

Table 1 Randomized placebo-controlled trials of atypical antipsychotics in the treatment of Alzheimer’s disease with psychosis

Study	Agent	N	Outcome measure	Outcome
Street et al^Citation10	Olanzapine 5 mg, 10 mg versus placebo	206	NPI psychosis subscale	5 mg and 10 mg superior to placebo, 15 mg not superior to placebo
De Deyn et al^Citation11	Olanzapine 1.0 mg, 2.5 mg, 5.0 mg, 7.5 mg versus placebo	652	NPI psychosis subscale	7.5 mg superior to placebo; 1.0 mg, 2.5 mg, 5.0 mg not superior to placebo
De Deyn et al^Citation13	Aripiprazole versus placebo	208	BPRS psychosis subscale; NPI psychosis subscale	Mean dose 10 mg superior to placebo on BPRS psychosis subscale but not NPI psychosis subscale
Mintzer et al^Citation14	Aripiprazole 2 mg, 5 mg, 10 mg versus placebo	487	NPI psychosis subscale	10 mg superior to placebo, 2 mg, 5 mg not superior to placebo
Tariot et al^Citation15	Quetiapine versus haloperidol versus placebo	284	BPRS thought disturbance	Mean dose 96.9 mg quetiapine, 1.9 mg haloperidol, neither superior to placebo
Katz et al^Citation20 Katz et al^Citation16 De Deyn et al^Citation17 Brodaty et al^Citation18 Mintzer et al^Citation19	Risperidone vs placebo	941	Meta-analysis of BEHAVE-AD psychosis subscale	Mean dose 1.09 mg risperidone superior to placebo, effect size 0.154 (range 95% CI, 0.038–0.269)
Sultzer et al^Citation12	Olanzapine versus quetiapine versus risperidone versus placebo	421	BPRS psychosis subscale; hostile suspiciousness factor	Mean dose olanzapine 5.5 mg superior to placebo on hostile suspiciousness but not psychosis subscale; 56.5 mg quetiapine not superior to placebo; risperidone 1 mg superior to placebo on both psychosis and hostile suspiciousness subscale

Abbreviations: BEHAVE-AD, Behavioral Pathology in Alzheimer’s Disease scale; BPRS, Brief Psychiatric Rating Scale; N, number; NPI, Neuropsychiatric Inventory; CI, confidence interval.

StreetJSClarkWSGannonKSOlanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study GroupArch Gen Psychiatry2000571096897611015815

 PubMed Web of Science ®Google Scholar

De DeynPPCarrascoMMDeberdtWOlanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s diseaseInt J Geriatr Psychiatry200419211512614758577

 PubMed Web of Science ®Google Scholar

De DeynPJesteDVSwaninkRAripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled studyJ Clin Psychopharmacol200525546346716160622

 PubMed Web of Science ®Google Scholar

MintzerJETuneLEBrederCDAripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed dosesAm J Geriatr Psychiatry2007151191893117974864

 PubMed Web of Science ®Google Scholar

TariotPNSchneiderLKatzIRQuetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trialAm J Geriatr Psychiatry200614976777616905684

 PubMed Web of Science ®Google Scholar

KatzIde DeynPPMintzerJGreenspanAZhuYBrodatyHThe efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trialsInt J Geriatr Psychiatry200722547548417471598

 PubMed Web of Science ®Google Scholar

KatzIRJesteDVMintzerJEClydeCNapolitanoJBrecherMComparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study GroupJ Clin Psychiatry199960210711510084637

 PubMed Web of Science ®Google Scholar

De DeynPPRabheruKRasmussenAA randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementiaNeurology199953594695510496251

 PubMed Web of Science ®Google Scholar

BrodatyHAmesDSnowdonJA randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementiaJ Clin Psychiatry200364213414312633121

 PubMed Web of Science ®Google Scholar

MintzerJGreenspanACaersIRisperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trialAm J Geriatr Psychiatry200614328029116505133

 PubMed Web of Science ®Google Scholar

SultzerDLDavisSMTariotPNCATIE-AD Study GroupClinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trialAm J Psychiatry2008165784485418519523

 PubMed Web of Science ®Google Scholar